Zuo Jiebin, Wang Panpan, Xue Kewen, Tan Yuwen, Zhang Ting, Li Yang, He Feixiang, Wu Weikun, Yan Zhixiang, Cong Li, Li Gang
Cardiac Surgery and Structural Heart Disease Unit of Cardiovascular Center, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University and Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai), Zhuhai, China.
Microbiol Spectr. 2025 Apr;13(4):e0237024. doi: 10.1128/spectrum.02370-24. Epub 2025 Feb 19.
Although lipid metabolism and gut microbiota dysregulation are known to participate in cardiovascular disease, few studies have examined these alterations and associations in acute myocardial infarction (AMI) patients. This study reveals altered and associated lipid metabolism and gut microbiome based on proteomic and lipidomic analyses of fecal and plasma samples from 30 patients with AMI and 33 healthy volunteers. Twenty-three differential plasma lipids, nine altered fecal lipids, and nine differential fecal bacterial species were identified in AMI patients relative to healthy volunteers, with nine plasma lipids, three fecal lipids, and two fecal bacteria as potential biomarkers. Correlation analysis revealed that the abundances of and were positively correlated with sphingosine and ceramide levels, respectively. and were correlated with blood lipid indicators (total cholesterol, triglycerides, and low-density lipoprotein-C), and , , and were associated with myocardial injury indicators (cTnI, CK, CK-MB, LDH, and BNP). This study identified potential lipid and gut microbe biomarkers and their associations in AMI patients.IMPORTANCEAcute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. While lipid metabolism and gut microbiota are known to play important roles in cardiovascular diseases, their interactions in the context of AMI are not fully understood. In this study, we explore the lipidomic and microbiome alterations in AMI patients, identifying key biomarkers associated with myocardial injury. By correlating specific lipid changes with bacterial species in fecal samples, we highlight the potential of lipid-microbe interactions in the pathogenesis of AMI. These findings provide novel insights into the complex mechanisms underlying AMI and suggest potential targets for early diagnosis and therapeutic interventions aimed at modulating lipid and microbial profiles to improve patient outcomes.
虽然已知脂质代谢和肠道微生物群失调参与心血管疾病，但很少有研究在急性心肌梗死（AMI）患者中检测这些改变及关联。本研究基于对30例AMI患者和33名健康志愿者的粪便及血浆样本进行蛋白质组学和脂质组学分析，揭示了脂质代谢和肠道微生物群的改变及关联。与健康志愿者相比，在AMI患者中鉴定出23种差异血浆脂质、9种改变的粪便脂质和9种差异粪便细菌种类，其中9种血浆脂质、3种粪便脂质和2种粪便细菌作为潜在生物标志物。相关性分析显示，[此处原文缺失具体指标]的丰度分别与鞘氨醇和神经酰胺水平呈正相关。[此处原文缺失具体指标]与血脂指标（总胆固醇、甘油三酯和低密度脂蛋白-C）相关，[此处原文缺失具体指标]与心肌损伤指标（肌钙蛋白I、肌酸激酶、肌酸激酶同工酶、乳酸脱氢酶和脑钠肽）相关。本研究确定了AMI患者中潜在的脂质和肠道微生物生物标志物及其关联。
重要性
急性心肌梗死（AMI）仍然是全球发病和死亡的主要原因。虽然已知脂质代谢和肠道微生物群在心血管疾病中起重要作用，但它们在AMI背景下的相互作用尚未完全了解。在本研究中，我们探索了AMI患者的脂质组学和微生物群改变，确定了与心肌损伤相关的关键生物标志物。通过将粪便样本中的特定脂质变化与细菌种类相关联，我们强调了脂质-微生物相互作用在AMI发病机制中的潜力。这些发现为AMI潜在的复杂机制提供了新见解，并提出了早期诊断和治疗干预的潜在靶点，旨在调节脂质和微生物谱以改善患者预后。
